Molecular Oncology Accepted into Thomson Reuters Index

Amsterdam, 25 February 2009 – Molecular Oncology (MOLONC), published by Elsevier on behalf of the Federation of European Biochemical Societies (FEBS), has been accepted by Thomson Reuters™ (formerly ISI), for inclusion in the Science Citation Index Expanded (SciSearch), Biosis Previews and Biological Abstracts.

MOLONC (published 6 times a year from January 1, 2009) highlights new discoveries, approaches, as well as technical developments, in basic, clinical and discovery-driven translational research. The first issue of MOLONC was published in June 2007 and has been managed from its inception by Prof. Julio E. Celis, Director of the Institute of Cancer Biology at the Danish Cancer Society in Copenhagen and Editor-in-Chief of Molecular Oncology.

“This is an excellent development, and demonstrates the high calibre of the journal. The editors are dedicated to making this journal a key source of ground-breaking research in this very exciting and stimulating field”, said Julio Celis.

Eleftherios P. Diamandis, Division Head of Clinical Biochemistry in the Department of Laboratory Medicine and Pathobiology at the University of Toronto in Ontario, Canada and a member of the Editorial Board of MOLONC commented, “This is a major milestone. I have no doubt that MOLONC will become a key journal in the field”

Anne Kitson, Senior Vice-President Life Sciences, at Elsevier added, “This is an exceptional achievement for a journal that is just 18 months old in this fast-moving and highly competitive field. It is indeed recognition of the exemplary work of our highly prestigious editor-in-chief, Julio Celis and his dedicated editorial board members.”

FEBS having pioneered the creation of scientific publication forums for European life scientists by its two leading journals, the FEBS Journal and FEBS Letters, is happy to see the progress of its third journal Molecular Oncology.

The 2009 Impact Factor will be the first Impact Factor for MOLONC. Coverage starts from Volume 1, 2007.

# # #

Molecular Oncology
Covers reviews, original articles, technical notes, editorials, news & views (commentary, science policy issues, ethical and legal issues, patient organisations, industry needs and alliances, regulatory issues, news items), letters to the editor, conference announcements, advertisements. The journal also publishes thematic Issues.
A main feature of the journal is to provide an international forum for debating cancer issues, and for integrating the input of all the stakeholders.
Topics include key biological processes such as cell cycle, emerging technologies, cancer genetics, Minimal residual disease, pre-malignant lesions, cancer micro-environment, molecular pathology, tumor immunology, translational research, cancer therapy, drug design, immunotherapy, combination therapies, resistance, and individualized treatment, chemotherapy, radiotherapy and surgery, clinical pharmacology, clinical trials, integration of basic science into cancer clinical trials, epidemiology and prevention, infrastructures (biobanks, databases, genomic resources).

Federation of European Biochemical Societies (FEBS)
FEBS is a federation of learned societies with over 40,000 members and a charity established for the public benefit to advance research and education in Biochemistry and Molecular Biology and related life sciences. The federation supports short- and long-term fellowships, advanced courses and workshops, and a variety of events to increase the public awareness of science. In addition, FEBS arranges for the publication of high quality peer-reviewed research journals in the life sciences.

For more information about FEBS: www.febs.org

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact:
Carl Schwarz
Elsevier
+31 20 485 2355
c.schwarz@elsevier.com